Loading...
  • murine
  • In vitro 50% inhibitory concentration (IC(50) ) data alone are not sufficient to guide the choice of a tyrosine kinase inhibitor (TKI) in the presence of a mutant breakpoint cluster region-v-abl Abelson murine leukemia viral oncogene homolog (BCR-ABL) clone, because there is a lack of data regarding how well such IC(50) values correlate with clinical response. (uptodate.com)
  • lymphoid
  • Autopsies of the victims suggested that profound lymphoid and myeloid suppression had occurred after exposure. (wikipedia.org)
  • Discovery of genetic mutations underlining these eosinophilia syndromes lead to their removal from CEL-NOS or HES categories and classification as myeloid and lymphoid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, FGFR1, and, tentatively, PCMA-JAK2. (wikipedia.org)
  • cancer
  • As Musashi2 is involved in the generation of hematopoietic cells, it is also linked with cancer pathologies: It has been found that MSI2 plays an important role in myeloid leukemia. (wikipedia.org)
  • Findings
  • APPROVAL WAS BASED on findings in an open-label phase III trial (BFORE) in which 536 patients were randomized to receive oral bosutinib at 400 mg once daily (n = 268) or oral imatinib at 400 mg once daily (n = 268). (ascopost.com)
  • multinational
  • Radotinib completed a multi-national Phase II clinical trial study in 2012 and in August 2011, Ilyang initiated a Phase III, multinational, multi-center, open-label, randomized study for first-line indication. (wikipedia.org)
  • Clinical
  • citation needed] The PACE (Ponatinib Ph+ ALL and CML Evaluation) pivotal phase II trial started enrolling patients in September 2010 and is designed to provide definitive clinical data for regulatory approval in this setting. (wikipedia.org)
  • versus
  • The EPIC (Evaluation of Ponatinib versus Imatinib in CML) phase-III trial began in June 2012 and was halted[clarification needed] on October 18, 2013. (wikipedia.org)
  • Study
  • Between December 2007 and October 2009 two hundred patients with CML in chronic phase were included in the study. (tjh.com.tr)
  • Led by Dr. Huisheng Ai and his medical team at MST International Clinic for Leukemia in the 307th Hospital of Chinese People's Liberation Army located in Beijing, multicenter collaborative study on Microtransplantation has started since 2013 in 9 authoritative blood institutes from China, Duke University and Keck School of Medicine-University of Southern California in United States, University of Sydney in Australia and University of Montreal in Canada. (wikipedia.org)
  • In June 2009, results of a long-term open label Phase II study were published, which investigated the use of omacetaxine infusions in CML patients. (wikipedia.org)
  • cell
  • Within the hematopoietic system, MSI2 is highly expressed in the most primitive progenitors, in stem cell compartments, and its overexpression has been found in myeloid leukemia cell lines. (wikipedia.org)
  • In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle. (wikipedia.org)
  • bone
  • In this phase, 10 to 19 % of the cells in the blood and bone marrow are blast cells (immature blood cells). (wikipedia.org)
  • It is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. (wikipedia.org)
  • Absent these causes, patients were diagnosed in the World Health Organization's classification as having either 1) Chronic eosinophilic leukemia, not otherwise specified, (CEL-NOS) if blood or bone marrow blast cells exceeded 2% or 5% of total nucleated cells, respectively, and other criteria were met or 2) idiopathic hypereosinophilic syndrome (HES) if there was evidence of eosinophil-induced tissue damage but no criteria indicating chronic eosinophilic leukemia. (wikipedia.org)
  • commonly
  • Farber met resistance to conducting his studies at a time when the commonly held medical belief was that leukemia was incurable, and that the children should be allowed to die in peace. (wikipedia.org)
  • studies
  • SM101 - As of 2015[update], had completed Phase IIA studies in idiopathic thrombocytopenic purpura SM201 / SM211 SM301 BAX 923 - a biosimilar version of Adalimumab. (wikipedia.org)